Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.
1/5 보강
Systemic mastocytosis is a malignant neoplasm classically driven by the KIT D816V mutation.
APA
Chernak BJ, Rampal R (2026). Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.. Leukemia & lymphoma, 67(4), 785-795. https://doi.org/10.1080/10428194.2025.2604560
MLA
Chernak BJ, et al.. "Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.." Leukemia & lymphoma, vol. 67, no. 4, 2026, pp. 785-795.
PMID
41518005 ↗
Abstract 한글 요약
Systemic mastocytosis is a malignant neoplasm classically driven by the KIT D816V mutation. Due to the range of clinical outcomes in these patients, the diagnosis and subclassification of the disease is complex but critical to understanding management, prognosis and therapeutic approaches. In those with non-advanced systemic mastocytosis, treatment decisions are tailored towards symptom improvement, whereas in advanced disease antiproliferative agents become more critical as outcomes resemble that of other myeloid neoplasms. With the advent of novel targeted therapies, the use of these agents have begun to expand their use in both non-advanced and advanced disease. This review will highlight the pathophysiology of systemic mastocytosis and offer a simplified approach to the clinical evaluation and diagnostic criteria to stratify patients by subtype. Further, management approaches in non-advanced, symptomatic disease and those with advanced disease in the era of targeted therapies are reviewed in detail.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.